We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways.
At Revolution Medicines, we combine our understanding of genetic drivers and adaptive resistance mechanisms in cancer with robust drug discovery and medicinal chemistry capabilities to create small molecules that target atypical binding sites on these proteins. We are using our innovation engine to develop a deep pipeline of novel targeted therapies to inhibit critical signaling nodes within the RAS and mTOR pathways.
Our most advanced product candidate, RMC-4630, is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway. In collaboration with our partner, Sanofi, we are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types harboring specific oncogenic mutations.
We are also developing a portfolio of mutant-selective RAS inhibitors that we believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). Initially, we will prioritize four mutant RAS(ON) targets - KRASG12C, KRASG13C, KRASG12D and NRASG12C.